ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 10 for:    CANOPY

Incidence of Acute Renal Failure Associated With Iodinated Contrast Agents in Pediatrics (CANOPY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02955979
Recruitment Status : Recruiting
First Posted : November 4, 2016
Last Update Posted : February 16, 2018
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Saint Etienne

Brief Summary:

Iodinated contrast media are now frequently used in diagnostic imaging exams, including pediatrics.

In adults, the acute renal failure (ARF) associated with contrast agents (CA-AKI) occur in 3-33% of exposed patients, especially as the patient is fragile, has comorbidities or pre-existing renal aggression .

In children, the prevalence of this little known disease is probably underestimated.

The investigators intend to conduct a prospective epidemiological study, to estimate the impact of the acute renale failure to iodinated contrast agents in pediatrics.


Condition or disease Intervention/treatment
Acute Renal Insufficiency Other: CT scan with iodinated contrast agents

Detailed Description:

Patients will be included those of pediatric emergencies, Hospitalization Unit of Short Duration pediatric, pediatric intensive care and pediatric resuscitation. The acute renale failure will be estimated on the basis of criteria KDIGO (score of kidney disease) group in 2012 to 48 hours a computed tomography (CT) scan with injection of contrast media, based on a change in creatinine clearance of the estimated according to the formula Schwartz revised in 2009 and / or diuresis.

Patient characteristics will be identified in order to establish risk factors.


Study Type : Observational
Estimated Enrollment : 500 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Incidence of Acute Renal Failure Associated With Iodinated Contrast Agents in Pediatrics. Study CANOPY. Prospective Multicenter Study
Study Start Date : December 8, 2016
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
CT scan with iodinated contrast agents
Patients under 16 years old and must pass a CT scan with iodinated contrast agents. The following data will be collected in the medical record (creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern).
Other: CT scan with iodinated contrast agents

Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.

After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.

Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary.




Primary Outcome Measures :
  1. Creatinine [ Time Frame: change from baseline creatinine at 7 days ]
    data gathered in the medical file

  2. Diuresis [ Time Frame: change from baseline diuresis at 7 days ]
    data gathered in the medical file


Secondary Outcome Measures :
  1. Readmission [ Time Frame: at 7 days ]
    Number of patients with no or having an adverse event during the readmission.

  2. Hospitalization in intensive care [ Time Frame: at 7 days ]
    Number of patients with no or having an adverse event during the hospitalization in intensive care.

  3. Renal replacement [ Time Frame: at 7 days ]
    Number of patients with no or having an adverse event during the renal replacement.

  4. Death [ Time Frame: at 7 days ]
    Number of dead



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 16 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients less than 16 years and who enjoys receiving an injected CT.
Criteria

Inclusion Criteria:

  • Patients under 16 years admitted to a participating service
  • Patient receiving an injected CT scan

Exclusion Criteria:

  • Prior Inclusion in the study during an earlier review.
  • Opposition of parents.
  • Chronic renal failure or end-stage requiring renal replacement in the long term.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02955979


Contacts
Contact: Olivier MORY, MD (0)77828134 ext +33 olivier.mory@chu-st-etienne.fr
Contact: PEURIERE Marie, CRA (0)477829272 ext +33 marie.peuriere@chu-st-etienne.fr

Locations
France
CHU de Lyon Recruiting
Lyon, France, 69310
Contact: Etienne Javouhey, MD PhD    (0)472129735 ext +33    etienne.javouhey@chu-lyon.fr   
Principal Investigator: Etienne Javouhey, MD PhD         
Sub-Investigator: Yves Gillet, MD PhD         
Chu Saint-Etienne Recruiting
Saint Etienne, France, 42055
Contact: Olivier MORY, MD    (0)477828632 ext +33    olivier.mory@chu-st-etienne.fr   
Principal Investigator: Olivier MORY, MD         
Sub-Investigator: Aymeric CANTAIS, MD         
Sub-Investigator: Hugues PATURAL, MD PhD         
Sponsors and Collaborators
Centre Hospitalier Universitaire de Saint Etienne
Investigators
Principal Investigator: Olivier MORY, MD CHU SAINT-ETIENNE

Responsible Party: Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier: NCT02955979     History of Changes
Other Study ID Numbers: 1608041
Y6D1846194a ( Registry Identifier: CNIL )
16-532bis ( Other Identifier: CCTIRS )
First Posted: November 4, 2016    Key Record Dates
Last Update Posted: February 16, 2018
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Centre Hospitalier Universitaire de Saint Etienne:
acute renal insufficiency
Iodinated Contrast Agents
pediatric

Additional relevant MeSH terms:
Renal Insufficiency
Acute Kidney Injury
Kidney Diseases
Urologic Diseases